REGULATORY

Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision

October 24, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Members of a powerful government panel on October 21 continued to push for a dramatic overhaul in the drug pricing system, including annual price revisions, blaming drug spending as the key culprit of Japan’s ballooning social security expenditures. “There is…

To read the full story

Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
October 17, 2016
Key Govt Panel Sets Sights on Pricy Meds
August 9, 2016

REGULATORY

Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
Japan Cabinet OKs Record Social Security Spending in FY2026 Budget, 105 Billion Yen in Drug Price Cuts
December 26, 2025
MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…